Aromatase inhibitors (AIs) are becoming the hormonal ... standard of 5 years of adjuvant tamoxifen and support using an AI (exemestane, anastrozole or letrozole) following tamoxifen for 2 ...

Studying the possible association between AI and cognitive dysfunction has accelerated over the past 7 years. A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or ...

Aromatase inhibitors are able to block the biosynthesis of estrogen—a process that is essential in bone maturation, growth-plate fusion, and cessation of longitudinal growth. Aromatase ...

Aromatase inhibition could be an alternative to testosterone administration to mitigate declining androgen production in hypogonadal older men. Unlike testosterone replacement, aromatase ...

“We are excited to advance our first AI-designed ATR inhibitors into preclinical testing,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “This represents a major step in ...

In a long awaited approveall, The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in ...

In September 2024, Rakovina announced its partnership with Variational AI to leverage the Enki™ generative AI platform for the development of next-generation DNA Damage Response (DDR) inhibitors.

VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through ...

The current preferred approach involves combining endocrine therapy—using aromatase inhibitors or fulvestrant—with CDK4/6 inhibitors. The approval of CDK4/6 inhibitors has significantly ...